References of "Hiligsmann, Mickaël"
     in
Bookmark and Share    
Full Text
Peer Reviewed
See detailPlace of residence as a risk factor for hip fracture? A case-control 3-year study
Bruyère, Olivier ULg; Pieck, C.; Hiligsmann, Mickaël ULg et al

in Annals of the Rheumatic Diseases (2008, June), 67(Suppl.II), 428

Detailed reference viewed: 12 (5 ULg)
Full Text
Peer Reviewed
See detailRelationship between long-term changes in femoral neck bone mineral density and hip fracture incidence in untreated postmenopausal osteoporotic women
Bruyère, Olivier ULg; Brandi, M.; Vellas, B. et al

in Annals of the Rheumatic Diseases (2008, June), 67(Suppl.II), 403

Detailed reference viewed: 10 (3 ULg)
Full Text
Peer Reviewed
See detailEfficiency of calcium and vitamin D supplementation in the management of osteoporosis
Hiligsmann, Mickaël ULg; Bruyère, Olivier ULg; Ethgen, Olivier ULg et al

in Osteoporosis International (2008, April), 19(S1), 113

Detailed reference viewed: 26 (12 ULg)
Full Text
Peer Reviewed
See detailCost-effectiveness of mass screening and targeted biphosphonates treatment in osteoporosis
Hiligsmann, Mickaël ULg; Bruyère, Olivier ULg; Ethgen, Olivier ULg et al

in Osteoporosis International (2008, April), 19(S1), 117

Detailed reference viewed: 26 (10 ULg)
Full Text
Peer Reviewed
See detailCost-utility of strontium ranelate in the treatment of postmenopausal women
Hiligsmann, Mickaël ULg; Bruyère, Olivier ULg; Ethgen, Olivier ULg et al

in Osteoporosis International (2008, April), 19(S1), 6

Detailed reference viewed: 11 (5 ULg)
Full Text
Peer Reviewed
See detailEfficiency and recommendations for osteoporosis screening strategy
Hiligsmann, Mickaël ULg; Bruyère, Olivier ULg; Ethgen, Olivier ULg et al

in Osteoporosis International (2008, April), 19(S1), 116

Detailed reference viewed: 21 (11 ULg)
Full Text
Peer Reviewed
See detailPlace of residence as a risk factor for hip fracture? A case-control 3-year study
Bruyère, Olivier ULg; Pieck, C.; Hiligsmann, Mickaël ULg et al

in Osteoporosis International (2008, April), 19(Suppl.1), 200

Detailed reference viewed: 9 (4 ULg)
Full Text
Peer Reviewed
See detailChanges in femoral neck bone mineral density are associated with hip fracture incidence in untreated postmenopausal women
Bruyère, Olivier ULg; Brandi, M. L.; Vellas, B. et al

in Osteoporosis International (2008, April), 19(Suppl.1), 18-19

Detailed reference viewed: 6 (2 ULg)
Full Text
Peer Reviewed
See detailEvaluation économique de la campagne de dépistage de l'ostéoporose menée en Province de Liège avec le concours de Liège Province Santé
Hiligsmann, Mickaël ULg; Bruyère, Olivier ULg; Pire, Georges et al

in Revue Médicale de Liège (2008), 63(10), 588-94

The Province of Liege has conducted an osteoporosis screening strategy for women aged 50 to 69 years. The objective of this study is to investigate the economic characteristics of the screening strategy ... [more ▼]

The Province of Liege has conducted an osteoporosis screening strategy for women aged 50 to 69 years. The objective of this study is to investigate the economic characteristics of the screening strategy and to assess its cost-effectiveness, using a Markov microsimulation model. Our analyses suggest that the osteoporosis screening strategy is efficient if the medical community and the patients fulfill the recommendations of the Province of Liege health authorities and if persistence is optimized. Therefore, bone mineral density (BMD) measurement should be performed in all individuals with positive ultrasound screening; individuals having a positive BMD diagnosis should be treated and adherence to therapy should be increased. Furthermore, to improve the efficiency of the screening strategy, we suggest to target screening on women with one or more clinical risk factors, or on women aged 65 years and older. [less ▲]

Detailed reference viewed: 70 (29 ULg)
Full Text
Peer Reviewed
See detailRisque à long terme de survenue d'une fracture ostéoporotique en Belgique.
Hiligsmann, Mickaël ULg; Bruyère, Olivier ULg; Reginster, Jean-Yves ULg

in Revue Médicale de Liège (2008), 63(7-8), 480-487

This work has been realised to estimate the lifetime risk of osteoporotic fracture for Belgian men and women aged 50 and 60 years. Estimates were based on a microsimulation Markov model. They take account ... [more ▼]

This work has been realised to estimate the lifetime risk of osteoporotic fracture for Belgian men and women aged 50 and 60 years. Estimates were based on a microsimulation Markov model. They take account of the incidence of fracture as well as of life expectancy. Several approaches have been taken to model life expectancy. Our estimates also take account of future mortality reductions based on official estimates and secular trends in life expectancy. Lifetime risk of osteoporotic population (bone mineral density below -2.5 T-score) was also estimated. Lifetime risk of hip fracture and any major osteoporotic fracture (hip, clinical vertebral or wrist) were 20.5% and 39% respectively for women aged 60 years. Corresponding values for men were 7.9% and 14.8% and for osteoporotic women 32.3% and 53.4%. Our lifetime risk estimates re-emphasize that osteoporosis is a major public health problem and that its societal burden is likely to increase due to demographic changes. [less ▲]

Detailed reference viewed: 63 (18 ULg)
Full Text
Peer Reviewed
See detailLifetime absolute risk of hip and other osteoporotic fracture in Belgian women.
Hiligsmann, Mickaël ULg; Bruyère, Olivier ULg; Ethgen, Olivier ULg et al

in BONE (2008), 43(6), 991-4

OBJECTIVES: To estimate the lifetime absolute risks of hip and other osteoporotic fracture in Belgian women aged 60 years and to examine the effect of changes in baseline population fracture risk and ... [more ▼]

OBJECTIVES: To estimate the lifetime absolute risks of hip and other osteoporotic fracture in Belgian women aged 60 years and to examine the effect of changes in baseline population fracture risk and changes in life expectancy. MATERIALS AND METHODS: Estimates were performed using a Markov microsimulation model and were based on the incidence of first fracture as well as life expectancy. Baseline scenario included projected mortality rates and increasing fracture incidence by 1% per year. Alternative scenarios were performed on age, life expectancy and trends in fracture incidence. Lifetime fracture risk for osteoporotic population (T-score <or= -2.5) was also estimated. RESULTS: In the baseline scenario, lifetime absolute risks of hip fracture and of any major osteoporotic fracture (hip, clinical vertebral or wrist) were respectively 24.8% and 44.3%. Alternative scenarios showed that when assuming no change of age-specific fracture rates over time, these lifetime risks were 18.3% and 35.2%, while these values were 20.0% and 38.3% assuming no future mortality reductions. For osteoporotic women, these values were respectively 34.5% and 51.5%. CONCLUSION: We conclude that absolute lifetime fracture risks are substantial and that trends in fracture incidence and changes in life expectancy have a marked impact on absolute lifetime fracture risks. [less ▲]

Detailed reference viewed: 47 (12 ULg)
Full Text
Peer Reviewed
See detailStrontium ranelate: The first agent of a new therapeutic class in osteoporosis.
Neuprez, Audrey; Hiligsmann, Mickaël ULg; Scholtissen, Sophie ULg et al

in Advances in Therapy (2008), 25(12), 1235-56

Strontium ranelate is a new agent developed for the management of post-menopausal osteoporosis. It has a unique mode of action, based on an uncoupling between bone formation (increased) and bone ... [more ▼]

Strontium ranelate is a new agent developed for the management of post-menopausal osteoporosis. It has a unique mode of action, based on an uncoupling between bone formation (increased) and bone resorption (decreased). To review its effectiveness we searched the MEDLINE database from 1985 to 2008, as well as databases such as the Cochrane controlled register, for citations or relevant articles. After this extensive search of the literature, a critical appraisal of the data was obtained through a consensus meeting (AN, MH, SS, OB, and J-YR). We found that strontium ranelate reduces vertebral, nonvertebral, major nonvertebral, and hip fractures over 1, 3, 4, and 5 years. Its spectrum of activity covers women with osteopenia, osteoporosis, and severe osteoporosis. Elderly subjects also show a reduction in vertebral and nonvertebral fractures. Bone mineral density may be used as a monitoring tool for strontium ranelate, since early changes are predictive of long-term fracture reduction. Biochemical markers of bone turnover reflect the uncoupling between resorption and formation. The safety profile of strontium ranelate compares favorably with the other currently marketed antiosteoporosis medications. Preliminary results suggest that strontium ranelate is able to reduce the progression of spine osteoarthritis. In conclusion, strontium ranelate has the potential to be a candidate for first-line treatment of osteopenia and osteoporosis. However, further research is needed before suggesting its widespread use in osteoarthritis. [less ▲]

Detailed reference viewed: 35 (6 ULg)
Full Text
Peer Reviewed
See detailUtility values associated with osteoporotic fracture: a systematic review of the literature.
Hiligsmann, Mickaël ULg; Ethgen, Olivier ULg; Richy, Florent et al

in Calcified Tissue International (2008), 82(4), 288-92

We reviewed studies that have estimated the impact of osteoporotic fracture on quality-adjusted life years (QALY) and to determine reference values for countries that would like to carry out cost-utility ... [more ▼]

We reviewed studies that have estimated the impact of osteoporotic fracture on quality-adjusted life years (QALY) and to determine reference values for countries that would like to carry out cost-utility analyses but that do not have their own values. The computerized medical literature databases Medline and EMBASE were searched from January 1990 to December 2006. The search was carried out in two steps. The first step was to identify studies that related to quality of life in osteoporosis. As part of the second step, only the studies that translated quality of life into a utility value (one single value for health status ranging 0-1) and calculated a utility loss over a period of at least 1 year were selected. From the 152 studies identified in the first analysis, only 16 were retained after the second step. Ten studies investigated utility values for hip fractures, 11 for vertebral fractures, five for distal forearm fractures, and four for other osteoporotic fractures and fracture interactions. Utility values differed substantially between studies, partly due to the valuation technique used, the severity of fractures, and the sample size. This review suggests that there is no meaningful average value across different studies, different samples, different countries, or different instruments. Although we tried to determine the best available values, these values do not preclude the need for country-specific studies. Finally, we also make recommendations regarding the design and methodology for such studies. [less ▲]

Detailed reference viewed: 39 (8 ULg)
Full Text
Peer Reviewed
See detailAn Economic Evaluation of Quantitative Ultrasonometry as Pre-Screening Test for the Identification of Patients with Osteoporosis
Hiligsmann, Mickaël ULg; Ethgen, Olivier ULg; Bruyère, Olivier ULg et al

in Disease Management & Health Outcomes (2008), 16(6), 429-438

Background: Screening for osteoporosis has been recommended to identify patients at high risk of fracture in order to provide preventative treatment. Given the limited availability of dual-energy x-ray ... [more ▼]

Background: Screening for osteoporosis has been recommended to identify patients at high risk of fracture in order to provide preventative treatment. Given the limited availability of dual-energy x-ray absorptiometry (DXA) and health resources, quantitative ultrasonometry (QUS) has emerged as an attractive tool for the mass screening scenario. The objective of this study was to evaluate whether a screening strategy using QUS as a pre-screening tool for bone densitometry would be cost effective and, if so, at what cut-off thresholds. Methods: Decision analytic models were used to compare the cost effectiveness and cost utility of several screening strategies: DXA measurement alone and pre-screening strategies that use different QUS index cut-off thresholds. For each strategy, and for hypothetical cohorts of women, we estimated the number of DXA scans required, the number of osteoporotic patients detected and missed, the total screening cost, and the incremental cost per patient detected. A validated Markov microsimulation model with a lifetime horizon and from a healthcare perspective was also computed in order to estimate the cost per quality-adjusted life-year (QALY) gained of the alternative screening strategies combined with 5 years of alendronate therapy for women who have osteoporosis (T-score -2.5 or less). Results: The DXA strategy had the highest cost and the highest number of patients with osteoporosis detected. Pre-screening strategies using QUS reduced the number of DXA scans per patient with osteoporosis detected and the total screening cost but they also missed patients with osteoporosis as the QUS index decreased. Pre-screening strategies using QUS T-scores of 0.0, -0.5, -2.0, and -2.5 were dominated by extended dominance, as their incremental cost-effectiveness ratios (ICERs) and incremental cost-utility ratios (ICURs) were higher than that of the next more effective alternative. The cost-effectiveness and cost-utility frontiers included no screening, pre-screening using QUS T-scores of -1.0 and -1.5, and DXA measurement alone. Conclusion: These results suggest that QUS may be useful as a pre-screening tool for bone densitometry given the limited availability of DXA and health resources, and that the QUS index T-scores of -1.0 and -1.5 are the most appropriate index. [less ▲]

Detailed reference viewed: 34 (8 ULg)